Alok Khorana, MD, FACP, FASCO
@alokkhorana.bsky.social
Hardis Endowed Chair in Oncology Research, Prof of Medicine, Director GI Cancer Program, Cleveland Clinic. Physician/Scientist/Writer. Opinions mine. #MedSky #Oncosky
Our latest paper with @ClevelandClinic investigators and RoswellPark colleagues Iyer, Vadehra, Fountzilas finds distinct microbiotic profiles of early onset pancreatic cancer and an association with survival @myesmo.bsky.social
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma
Compelling evidence supports the biomarker potential of microbiome in pancreatic adenocarcinoma. Given the knowledge gap on the characteristics and si…
www.sciencedirect.com
July 8, 2025 at 1:53 PM
Our latest paper with @ClevelandClinic investigators and RoswellPark colleagues Iyer, Vadehra, Fountzilas finds distinct microbiotic profiles of early onset pancreatic cancer and an association with survival @myesmo.bsky.social
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Reposted by Alok Khorana, MD, FACP, FASCO
This is what we were waiting for. A direct comparison between apixaban and rivaroxaban for the treatment of acute VTE. Apixaban reduces bleeding risk in the first 3 months by >50%!
Practice changing investigator-initiated RCT.
#ISTH2025
Practice changing investigator-initiated RCT.
#ISTH2025
June 22, 2025 at 1:49 PM
This is what we were waiting for. A direct comparison between apixaban and rivaroxaban for the treatment of acute VTE. Apixaban reduces bleeding risk in the first 3 months by >50%!
Practice changing investigator-initiated RCT.
#ISTH2025
Practice changing investigator-initiated RCT.
#ISTH2025
Reposted by Alok Khorana, MD, FACP, FASCO
🩸 WaVE Study Alert!
In patients with acute CAT & weight >90kg, weight-based dalteparin (200 IU/kg) appears safe & effective.
🔹 Anti-Xa levels aligned with non-obese patients
🔹 Higher levels seen in those with bleeding
Important data to guide dosing CAT & obesity.
📍Presented by Dr. Wang at #ISTH2025
In patients with acute CAT & weight >90kg, weight-based dalteparin (200 IU/kg) appears safe & effective.
🔹 Anti-Xa levels aligned with non-obese patients
🔹 Higher levels seen in those with bleeding
Important data to guide dosing CAT & obesity.
📍Presented by Dr. Wang at #ISTH2025
June 24, 2025 at 7:08 PM
🩸 WaVE Study Alert!
In patients with acute CAT & weight >90kg, weight-based dalteparin (200 IU/kg) appears safe & effective.
🔹 Anti-Xa levels aligned with non-obese patients
🔹 Higher levels seen in those with bleeding
Important data to guide dosing CAT & obesity.
📍Presented by Dr. Wang at #ISTH2025
In patients with acute CAT & weight >90kg, weight-based dalteparin (200 IU/kg) appears safe & effective.
🔹 Anti-Xa levels aligned with non-obese patients
🔹 Higher levels seen in those with bleeding
Important data to guide dosing CAT & obesity.
📍Presented by Dr. Wang at #ISTH2025
Reposted by Alok Khorana, MD, FACP, FASCO
🚨 SPECTACULAR RCT at #ISTH2025!
Although non-inferiority to CTPA wasn’t shown, a negative SPECT V/Q scan led to low 3-month VTE risk—
✅ Supporting the safety of ruling out PE with a SPECT-based algorithm
📸 PE diagnosis rates matched other validated strategies
SPECTacular findings indeed! 🫁💥
Although non-inferiority to CTPA wasn’t shown, a negative SPECT V/Q scan led to low 3-month VTE risk—
✅ Supporting the safety of ruling out PE with a SPECT-based algorithm
📸 PE diagnosis rates matched other validated strategies
SPECTacular findings indeed! 🫁💥
June 24, 2025 at 7:15 PM
🚨 SPECTACULAR RCT at #ISTH2025!
Although non-inferiority to CTPA wasn’t shown, a negative SPECT V/Q scan led to low 3-month VTE risk—
✅ Supporting the safety of ruling out PE with a SPECT-based algorithm
📸 PE diagnosis rates matched other validated strategies
SPECTacular findings indeed! 🫁💥
Although non-inferiority to CTPA wasn’t shown, a negative SPECT V/Q scan led to low 3-month VTE risk—
✅ Supporting the safety of ruling out PE with a SPECT-based algorithm
📸 PE diagnosis rates matched other validated strategies
SPECTacular findings indeed! 🫁💥
Reposted by Alok Khorana, MD, FACP, FASCO
Meta-analysis on GLP-1RA (vs. placebo) and VTE:
🔹 PE rates significantly lower 📉
🔹 VTE rates lower but not statistically significant
🔹 No difference in DVT
🔹 Study design matters: RCTs vs. observational data
Accepted for publication in JTH!
#ISTH2025 #VTE #GLP1RA #Thrombosis
@jthjournal.bsky.social
🔹 PE rates significantly lower 📉
🔹 VTE rates lower but not statistically significant
🔹 No difference in DVT
🔹 Study design matters: RCTs vs. observational data
Accepted for publication in JTH!
#ISTH2025 #VTE #GLP1RA #Thrombosis
@jthjournal.bsky.social
June 23, 2025 at 7:43 PM
Meta-analysis on GLP-1RA (vs. placebo) and VTE:
🔹 PE rates significantly lower 📉
🔹 VTE rates lower but not statistically significant
🔹 No difference in DVT
🔹 Study design matters: RCTs vs. observational data
Accepted for publication in JTH!
#ISTH2025 #VTE #GLP1RA #Thrombosis
@jthjournal.bsky.social
🔹 PE rates significantly lower 📉
🔹 VTE rates lower but not statistically significant
🔹 No difference in DVT
🔹 Study design matters: RCTs vs. observational data
Accepted for publication in JTH!
#ISTH2025 #VTE #GLP1RA #Thrombosis
@jthjournal.bsky.social
Reposted by Alok Khorana, MD, FACP, FASCO
Implementation matters!
A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. #ISTH2025 #VTEprevention 🩸
@marycushmanmd.bsky.social
A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. #ISTH2025 #VTEprevention 🩸
@marycushmanmd.bsky.social
June 24, 2025 at 7:45 PM
Implementation matters!
A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. #ISTH2025 #VTEprevention 🩸
@marycushmanmd.bsky.social
A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. #ISTH2025 #VTEprevention 🩸
@marycushmanmd.bsky.social
Time to Treatment Initiation for the 30 Most Prevalent Cancer Types: Trends and Predictors of Change | JCO Oncology Practice ascopubs.org/doi/10.1200/...
Time to Treatment Initiation for the 30 Most Prevalent Cancer Types: Trends and Predictors of Change | JCO Oncology Practice
PURPOSEAs the complexity and need for cancer care services continue to grow, time to treatment
initiation (TTI) has been increasing across cancer types. Presently there are no comprehensive
analyses i...
ascopubs.org
May 22, 2025 at 12:32 AM
Time to Treatment Initiation for the 30 Most Prevalent Cancer Types: Trends and Predictors of Change | JCO Oncology Practice ascopubs.org/doi/10.1200/...
Reposted by Alok Khorana, MD, FACP, FASCO
#GI25 @ascocancer.bsky.social
Two trials on the tissue factor⛔️, pamrevlumab (PAM) in #PancreaticCancer, both by Dr. Piccozzi:
1⃣LAPIS, a R-Ph3 trial of chemo +/- PAM for LAPC, Oral Abstract #675
2⃣The Precision Promise trial @pancan.bsky.social of PAM+gem/nab-pac for mPDAC, Oral Abstract # 673
Two trials on the tissue factor⛔️, pamrevlumab (PAM) in #PancreaticCancer, both by Dr. Piccozzi:
1⃣LAPIS, a R-Ph3 trial of chemo +/- PAM for LAPC, Oral Abstract #675
2⃣The Precision Promise trial @pancan.bsky.social of PAM+gem/nab-pac for mPDAC, Oral Abstract # 673
January 11, 2025 at 6:54 PM
#GI25 @ascocancer.bsky.social
Two trials on the tissue factor⛔️, pamrevlumab (PAM) in #PancreaticCancer, both by Dr. Piccozzi:
1⃣LAPIS, a R-Ph3 trial of chemo +/- PAM for LAPC, Oral Abstract #675
2⃣The Precision Promise trial @pancan.bsky.social of PAM+gem/nab-pac for mPDAC, Oral Abstract # 673
Two trials on the tissue factor⛔️, pamrevlumab (PAM) in #PancreaticCancer, both by Dr. Piccozzi:
1⃣LAPIS, a R-Ph3 trial of chemo +/- PAM for LAPC, Oral Abstract #675
2⃣The Precision Promise trial @pancan.bsky.social of PAM+gem/nab-pac for mPDAC, Oral Abstract # 673
Reposted by Alok Khorana, MD, FACP, FASCO
Thrilled to listen to the incredible #GI25 keynote speaker @pamelakunzmd.bsky.social inspiring us all with her leadership in inclusive science in GI oncology! @ascopost.bsky.social @halletjulie.bsky.social @drcnclarke.bsky.social @rachnatshroff.bsky.social @nanets.bsky.social
January 23, 2025 at 10:41 PM
Thrilled to listen to the incredible #GI25 keynote speaker @pamelakunzmd.bsky.social inspiring us all with her leadership in inclusive science in GI oncology! @ascopost.bsky.social @halletjulie.bsky.social @drcnclarke.bsky.social @rachnatshroff.bsky.social @nanets.bsky.social
Reposted by Alok Khorana, MD, FACP, FASCO
HPV vaccines prevent cancer and save lives. As an oncologist in training, I regularly see the burden and suffering that HPV related cancers cause for my patients. It will involve continuing to build trust, but addressing vaccine hesitancy is vital. #radonc #gyncsm academic.oup.com/jid/advance-...
January 24, 2025 at 1:08 AM
HPV vaccines prevent cancer and save lives. As an oncologist in training, I regularly see the burden and suffering that HPV related cancers cause for my patients. It will involve continuing to build trust, but addressing vaccine hesitancy is vital. #radonc #gyncsm academic.oup.com/jid/advance-...
Reposted by Alok Khorana, MD, FACP, FASCO
Important for patients unable to access Creon for financial reasons #pancreaticcancer
Oncology dietitian Meghan Laszlo explains how pancreatic enzyme replacement drug Creon works and available alternatives. letswinpc.org/disease-mana...
#PancreaticCancer
#PancreaticCancer
Exploring Alternatives to Creon for Pancreatic Enzyme Replacement Therapy
Oncology dietitian Meghan Laszlo explains how pancreatic enzyme replacement drug Creon works and available alternatives.
letswinpc.org
November 19, 2024 at 10:57 AM
Important for patients unable to access Creon for financial reasons #pancreaticcancer
Reposted by Alok Khorana, MD, FACP, FASCO
Nice new validation of Ang Li's risk score in JTH, first in non-US population (albeit using diagnostic codes rather than chart review)
www.jthjournal.org/article/S153...
www.jthjournal.org/article/S153...
DEFINE_ME
www.jthjournal.org
November 19, 2024 at 2:17 AM
Reposted by Alok Khorana, MD, FACP, FASCO
James Van Der Beek, Jenna Fischer and the rise of young people getting cancer in @usatoday.com
www.usatoday.com/story/life/h...
www.usatoday.com/story/life/h...
James Van Der Beek, Jenna Fischer and the rise of young people getting cancer
Why are young people getting cancer at higher rates? No one knows, but here's how to stay proactive and vigilant.
www.usatoday.com
November 16, 2024 at 1:14 AM
James Van Der Beek, Jenna Fischer and the rise of young people getting cancer in @usatoday.com
www.usatoday.com/story/life/h...
www.usatoday.com/story/life/h...
Nice new validation of Ang Li's risk score in JTH, first in non-US population (albeit using diagnostic codes rather than chart review)
www.jthjournal.org/article/S153...
www.jthjournal.org/article/S153...
DEFINE_ME
www.jthjournal.org
November 14, 2024 at 6:15 PM
Nice new validation of Ang Li's risk score in JTH, first in non-US population (albeit using diagnostic codes rather than chart review)
www.jthjournal.org/article/S153...
www.jthjournal.org/article/S153...
Reposted by Alok Khorana, MD, FACP, FASCO
Reposted by Alok Khorana, MD, FACP, FASCO
November 12, 2024 at 8:57 PM
Reposted by Alok Khorana, MD, FACP, FASCO
I'm making a Starter Pack of Oncology accounts that will include health care (clinical & research), advocates, & patients.
If you're unfamiliar, Starter Packs are a 📃 of accts that can be easily followed
Please reply to this post with any recommendations, including yourself
~dsp
#oncosky
#medsky
If you're unfamiliar, Starter Packs are a 📃 of accts that can be easily followed
Please reply to this post with any recommendations, including yourself
~dsp
#oncosky
#medsky
November 11, 2024 at 9:53 AM
Found this very useful as a newbie
If you’re new to BlueSky and looking for your people, there’s a very useful searchable directory of starter packs to help you find individuals and communities in particular topic areas:
blueskydirectory.com/starter-pack...
blueskydirectory.com/starter-pack...
All - Bluesky Directory
A curated collection of all things relating to the Blue Sky social media platform.
blueskydirectory.com
November 11, 2024 at 11:23 PM
Found this very useful as a newbie
Reposted by Alok Khorana, MD, FACP, FASCO
High-resolution of cancer. Unprecedented. A brief review of what we've just learned from 17 new papers in the latest edition of Ground Truths.
It's free, open-access.
erictopol.substack.com/p/cancer-sci...
It's free, open-access.
erictopol.substack.com/p/cancer-sci...
Cancer Science in On a Tear
New insights on evolution, resistance, and therapies
erictopol.substack.com
November 10, 2024 at 6:51 PM
High-resolution of cancer. Unprecedented. A brief review of what we've just learned from 17 new papers in the latest edition of Ground Truths.
It's free, open-access.
erictopol.substack.com/p/cancer-sci...
It's free, open-access.
erictopol.substack.com/p/cancer-sci...
Reposted by Alok Khorana, MD, FACP, FASCO
Welcome new Bluesky users! There's lots of advice being posted for new users at the moment. This thread is tailored for the STEM, academic, and medical people, and I hope this helps you find your community!
For starters, here's a starter pack full of medical accounts worth checking out!
For starters, here's a starter pack full of medical accounts worth checking out!
October 17, 2024 at 2:12 PM
Welcome new Bluesky users! There's lots of advice being posted for new users at the moment. This thread is tailored for the STEM, academic, and medical people, and I hope this helps you find your community!
For starters, here's a starter pack full of medical accounts worth checking out!
For starters, here's a starter pack full of medical accounts worth checking out!